H1N1 infection

Virology And Pathogenesis

The influenza A (H1N1) virus belongs to the family Orthomyxoviridae and the genus Influenza Virus A.
It is an enveloped, pleomorphic virus measuring 80 to 120 nm in diameter.
The genome features single-stranded, negative-sense RNA segmented into eight separate pieces, allowing for rapid genetic reassortment.
The viral envelope possesses two major surface glycoproteins critical for infection and host immune response:
- Hemagglutinin (HA): Facilitates viral attachment to host sialic acid receptors on the respiratory epithelium.
- Neuraminidase (NA): An enzyme that cleaves sialic acid residues to release newly formed viral particles from the host cell.

Antigenic Drift: Gradual point mutations within the HA and NA genes leading to seasonal variations and evasion of pre-existing immunity.
Antigenic Shift: Abrupt, major genetic changes resulting from the reassortment of gene segments between human and animal viruses, capable of triggering pandemics.
The 2009 pandemic strain (A[H1N1]pdm09) emerged as a novel triple reassortant virus containing genetic segments from North American swine, North American avian, human influenza, and Eurasian swine viruses.

The primary natural reservoirs are wild aquatic birds, while pigs act as mixing vessels possessing receptors for both avian and human viruses.
Transmission occurs predominantly via large respiratory droplets, fomites, and small-particle aerosols.
The incubation period typically spans 1 to 4 days, averaging 2 days.
Adults are communicable from 1 day prior to symptom onset until 5 to 7 days after onset, whereas children and immunocompromised individuals may shed the virus for 10 days or longer.
In India, transmission exhibits distinct biphasic seasonality, featuring a primary peak during the monsoon season (August to October) and a secondary peak in winter (January to March).

Children under 5 years of age, particularly those under 2 years.
Adults older than 65 years and pregnant women.
Individuals possessing chronic comorbidities, including respiratory, cardiac, renal, hepatic, or neurological diseases.
Immunocompromised patients and persons with morbid obesity.

The Government of India (MoHFW) categorizes illness severity to guide testing and antiviral utilization.

Category	Clinical Presentation	Patient Risk Status	Management Protocol
Category A (Mild)	Mild fever, cough, sore throat, body ache, headache, diarrhea.	No high-risk conditions.	Symptomatic treatment, home isolation. RT-PCR testing and Oseltamivir are strictly not required.
Category B1	Category A symptoms plus high-grade fever (≥102°F) and severe sore throat.	No high-risk conditions.	Home isolation. Initiate Oseltamivir immediately. No routine testing required.
Category B2	Category A symptoms (mild illness).	Presence of high-risk conditions or comorbidities.	Home isolation. Initiate Oseltamivir immediately. No routine testing required.
Category C (Severe)	Category A or B symptoms plus Red Flag signs: dyspnea, chest pain, hemoptysis, altered sensorium, hypotension, cyanosis, severe dehydration, or convulsions.	Any risk status.	Immediate hospitalization (ICU/isolation). Mandatory RT-PCR testing. Initiate empiric Oseltamivir immediately. Provide supportive care.

Oseltamivir serves as the definitive drug of choice and must ideally be initiated within 48 hours of symptom onset.
The standard therapeutic duration is 5 days.

Patient Weight / Age	Treatment Dose (Twice Daily For 5 Days)
< 15 kg	30 mg
15 – 23 kg	45 mg
24 – < 40 kg	60 mg
> 40 kg	75 mg
Infants < 3 months	12 mg
Infants 3 – 5 months	20 mg
Infants 6 – 11 months	25 mg

📛 Dosage Note for Oseltamivir

The Dose can be remembered as 3 mg/kg/dose twice daily, although guidelines and standard references give only weight band based dosing

Chemoprophylaxis: Administered to high-risk household contacts utilizing the same weight-based dose, but given once daily for a duration of 10 days.

High-priority groups include children with chronic medical conditions, immunodeficiency states, and neurodevelopmental disorders.
Healthy young children aged 6 months to 5 years constitute a priority group due to the high burden of morbidity.
Household contacts of high-risk children and infants under 6 months must be vaccinated to establish cocooning protection.

Inactivated Influenza Vaccine (IIV): Administered intramuscularly and safe for all patients, including immunocompromised hosts.
Live Attenuated Influenza Vaccine (LAIV): Administered intranasally; strictly contraindicated in children under 2 years, asthmatics, and immunocompromised patients.
Children aged 6 months to 8 years receiving the vaccine for the first time require two doses separated by at least 4 weeks.
Children previously vaccinated with at least two doses, and all children older than 9 years, require a single annual dose.